Arch Gynecol Obstet 2019 07 19;300(1):223-233. Epub 2019 Apr 19.
Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing, 100034, People's Republic of China.
Purpose: Ovarian hyperstimulation syndrome (OHSS) is a serious complication of assisted reproductive technology (ART) treatment. However, there are limited data regarding the ability of the luteal GnRH antagonist cetrorelix to reduce the incidence of moderate and severe OHSS, and the mechanism remains unclear. Thus, we designed a study to assess the effectiveness of cetrorelix to prevent early moderate and severe OHSS in high-risk patients undergoing controlled ovarian stimulation for IVF/ICSI. Read More